Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(3):387–393. doi: 10.1038/bjc.1996.370

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.

D Del Bufalo 1, C Cucco 1, C Leonetti 1, G Citro 1, I D'Agnano 1, M Benassi 1, T Geiser 1, G Zon 1, B Calabretta 1, G Zupi 1
PMCID: PMC2074645  PMID: 8695353

Abstract

We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the G1 phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.

Full text

PDF
388

Images in this article

389Figure 1
on p.389
391Figure 4
on p.391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alitalo K., Winqvist R., Lin C. C., de la Chapelle A., Schwab M., Bishop J. M. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4534–4538. doi: 10.1073/pnas.81.14.4534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Alitalo K., Winqvist R., Lin C. C., de la Chapelle A., Schwab M., Bishop J. M. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4534–4538. doi: 10.1073/pnas.81.14.4534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Arancia G., Leonetti C., Malorni W., Greco C., Formisano G., Marangolo M., Zupi G. Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice. J Cancer Res Clin Oncol. 1991;117(4):351–358. doi: 10.1007/BF01630719. [DOI] [PubMed] [Google Scholar]
  6. Berenbaum M. C. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981;35:269–335. doi: 10.1016/s0065-230x(08)60912-4. [DOI] [PubMed] [Google Scholar]
  7. Berenbaum M. C. The expected effect of a combination of agents: the general solution. J Theor Biol. 1985 Jun 7;114(3):413–431. doi: 10.1016/s0022-5193(85)80176-4. [DOI] [PubMed] [Google Scholar]
  8. Burgess T. L., Fisher E. F., Ross S. L., Bready J. V., Qian Y. X., Bayewitch L. A., Cohen A. M., Herrera C. J., Hu S. S., Kramer T. B. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4051–4055. doi: 10.1073/pnas.92.9.4051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res. 1991 Sep 1;51(17):4505–4510. [PubMed] [Google Scholar]
  10. Calabretta B., Nicolaides N. C. c-myb and growth control. Crit Rev Eukaryot Gene Expr. 1992;2(3):225–235. [PubMed] [Google Scholar]
  11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  12. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7031–7035. doi: 10.1073/pnas.89.15.7031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer. 1994 Mar;69(3):463–467. doi: 10.1038/bjc.1994.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Drewinko B., Loo T. L., Brown B., Gottlieb J. A., Freireich E. J. Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys. 1976 May;1(4):187–195. [PubMed] [Google Scholar]
  15. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  16. Funato T. [Circumventing drug resistance in human tumors by antisense ribozyme]. Gan To Kagaku Ryoho. 1994 Feb;21(3):336–342. [PubMed] [Google Scholar]
  17. Gentile F. P., Chiatti L., Mauro F., Briganti G., Floridi A., Benassi M. Interaction of cytotoxic agents: a rule-based system for computer-assisted cell survival analysis. Anticancer Res. 1992 May-Jun;12(3):637–643. [PubMed] [Google Scholar]
  18. Grandi M., Geroni C., Giuliani F. C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer. 1986 Sep;54(3):515–518. doi: 10.1038/bjc.1986.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hijiya N., Zhang J., Ratajczak M. Z., Kant J. A., DeRiel K., Herlyn M., Zon G., Gewirtz A. M. Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4499–4503. doi: 10.1073/pnas.91.10.4499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lipsick J. S., Boyle W. J. c-myb protein expression is a late event during T-lymphocyte activation. Mol Cell Biol. 1987 Sep;7(9):3358–3360. doi: 10.1128/mcb.7.9.3358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Majello B., Kenyon L. C., Dalla-Favera R. Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9636–9640. doi: 10.1073/pnas.83.24.9636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Melani C., Rivoltini L., Parmiani G., Calabretta B., Colombo M. P. Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res. 1991 Jun 1;51(11):2897–2901. [PubMed] [Google Scholar]
  23. Negroni A., Scarpa S., Romeo A., Ferrari S., Modesti A., Raschellà G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 1991 Oct;2(10):511–518. [PubMed] [Google Scholar]
  24. Nieborowska-Skórska M., Nakashima M., Ratajczak M., Steplewski Z., Calabretta B., Skórski T. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment? Folia Histochem Cytobiol. 1994;32(1):35–40. doi: 10.1007/BF02693351. [DOI] [PubMed] [Google Scholar]
  25. Ramsay R. G., Thompson M. A., Hayman J. A., Reid G., Gonda T. J., Whitehead R. H. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992 Oct;3(10):723–730. [PubMed] [Google Scholar]
  26. Raschellà G., Negroni A., Skorski T., Pucci S., Nieborowska-Skorska M., Romeo A., Calabretta B. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines. Cancer Res. 1992 Aug 1;52(15):4221–4226. [PubMed] [Google Scholar]
  27. Ratajczak M. Z., Kant J. A., Luger S. M., Hijiya N., Zhang J., Zon G., Gewirtz A. M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823–11827. doi: 10.1073/pnas.89.24.11823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rosenberg B. Fundamental studies with cisplatin. Cancer. 1985 May 15;55(10):2303–23l6. doi: 10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  29. Rowinsky E. K., Gilbert M. R., McGuire W. P., Noe D. A., Grochow L. B., Forastiere A. A., Ettinger D. S., Lubejko B. G., Clark B., Sartorius S. E. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991 Sep;9(9):1692–1703. doi: 10.1200/JCO.1991.9.9.1692. [DOI] [PubMed] [Google Scholar]
  30. Scheithauer W., Rosen H., Schiessel R., Schüller J., Karall M., Ernst F., Sebesta C., Kornek G., Hentschel E., Marczell A. Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin. Cancer. 1991 Mar 1;67(5):1294–1298. doi: 10.1002/1097-0142(19910301)67:5<1294::aid-cncr2820670504>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  31. Sklar M. D., Prochownik E. V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 1991 Apr 15;51(8):2118–2123. [PubMed] [Google Scholar]
  32. Stein C. A., Subasinghe C., Shinozuka K., Cohen J. S. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988 Apr 25;16(8):3209–3221. doi: 10.1093/nar/16.8.3209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thiele C. J., Cohen P. S., Israel M. A. Regulation of c-myb expression in human neuroblastoma cells during retinoic acid-induced differentiation. Mol Cell Biol. 1988 Apr;8(4):1677–1683. doi: 10.1128/mcb.8.4.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Torelli G., Venturelli D., Coló A., Zanni C., Selleri L., Moretti L., Calabretta B., Torelli U. Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa. Cancer Res. 1987 Oct 15;47(20):5266–5269. [PubMed] [Google Scholar]
  35. Venturelli D., Travali S., Calabretta B. Inhibition of T-cell proliferation by a MYB antisense oligomer is accompanied by selective down-regulation of DNA polymerase alpha expression. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5963–5967. doi: 10.1073/pnas.87.15.5963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yaswen P., Stampfer M. R., Ghosh K., Cohen J. S. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev. 1993 Spring;3(1):67–77. doi: 10.1089/ard.1993.3.67. [DOI] [PubMed] [Google Scholar]
  37. Yokoyama K., Imamoto F. Transcriptional control of the endogenous MYC protooncogene by antisense RNA. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7363–7367. doi: 10.1073/pnas.84.21.7363. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES